Chang Yu Wang

Array ( [id] => 16400159 [patent_doc_number] => 20200341017 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => 3D CELL CULTURE [patent_app_type] => utility [patent_app_number] => 16/757161 [patent_app_country] => US [patent_app_date] => 2018-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16486 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16757161 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16913977 [patent_doc_number] => 20210187069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => DOMINANT NEGATIVE SARM1 MOLECULES AS A THERAPEUTIC STRATEGY FOR NEURODEGENERATIVE DISEASES OR DISORDERS [patent_app_type] => utility [patent_app_number] => 16/757254 [patent_app_country] => US [patent_app_date] => 2018-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21596 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16757254 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17243753 [patent_doc_number] => 20210363496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => METHOD FOR OBTAINING ARTIFICIAL NEUROMUSCULAR JUNCTION FROM PLURIPOTENT STEM CELLS [patent_app_type] => utility [patent_app_number] => 16/757339 [patent_app_country] => US [patent_app_date] => 2018-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9032 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16757339 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16204877 [patent_doc_number] => 20200237867 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => METHODS AND DEVICES FOR PROMOTING NERVE GROWTH AND REGENERATION [patent_app_type] => utility [patent_app_number] => 16/755089 [patent_app_country] => US [patent_app_date] => 2018-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29751 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16755089 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15738425 [patent_doc_number] => 20200108100 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-09 [patent_title] => NEURAL STEM CELL THERAPY FOR STROKE [patent_app_type] => utility [patent_app_number] => 16/154059 [patent_app_country] => US [patent_app_date] => 2018-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14028 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16154059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14134313 [patent_doc_number] => 20190101546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-04 [patent_title] => METHODS OF TREATING STROKE [patent_app_type] => utility [patent_app_number] => 16/150882 [patent_app_country] => US [patent_app_date] => 2018-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19957 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16150882 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13990063 [patent_doc_number] => 20190064189 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => NEURONAL VIABILITY FACTOR AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/149420 [patent_app_country] => US [patent_app_date] => 2018-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8116 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16149420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16259973 [patent_doc_number] => 10751382 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-25 [patent_title] => Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide [patent_app_type] => utility [patent_app_number] => 16/148601 [patent_app_country] => US [patent_app_date] => 2018-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 34 [patent_no_of_words] => 29669 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 298 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16148601 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16238247 [patent_doc_number] => 20200255481 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => NEUROTOXIN-LIKE TOXIN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/651720 [patent_app_country] => US [patent_app_date] => 2018-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27628 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -144 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16651720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18347727 [patent_doc_number] => 20230135837 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => PROCESS FOR PREPARING A PLATELET LYSATE FRACTION, PLATELET LYSATE FRACTION AND ITS USE FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM [patent_app_type] => utility [patent_app_number] => 16/650070 [patent_app_country] => US [patent_app_date] => 2018-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8349 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16650070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13841125 [patent_doc_number] => 20190024047 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => MEDIUM FOR NEURAL STEM CELLS ENHANCING NEURAL DIFFERENTIATION ABILITY [patent_app_type] => utility [patent_app_number] => 16/144187 [patent_app_country] => US [patent_app_date] => 2018-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16144187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13827123 [patent_doc_number] => 20190017046 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => PREPARATION, MEMBER FOR PREPARATION, AND METHODS FOR MANUFACTURING THESE [patent_app_type] => utility [patent_app_number] => 16/144475 [patent_app_country] => US [patent_app_date] => 2018-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11032 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16144475 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283762 [patent_doc_number] => 20200277364 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF Fab [patent_app_type] => utility [patent_app_number] => 16/645877 [patent_app_country] => US [patent_app_date] => 2018-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16645877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14185309 [patent_doc_number] => 20190112359 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => Separation of Triple-Light Chain Antibodies Using Cation Exchange Chromatography [patent_app_type] => utility [patent_app_number] => 16/138177 [patent_app_country] => US [patent_app_date] => 2018-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12725 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16138177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16230570 [patent_doc_number] => 10738109 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-11 [patent_title] => Blood-brain barrier permeable peptide compositions comprising a VAB domain of an anti-amyloid-beta camelid single-domain heavy-chain only antibody [patent_app_type] => utility [patent_app_number] => 16/136058 [patent_app_country] => US [patent_app_date] => 2018-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 16 [patent_no_of_words] => 13679 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16136058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283969 [patent_doc_number] => 20200277571 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => METHOD FOR AMPLIFYING CONE PHOTORECEPTORS OR ROD PHOTORECEPTORS USING DORSALIZATION SIGNAL TRANSMITTER OR VENTRALIZATION SIGNAL TRANSMITTER [patent_app_type] => utility [patent_app_number] => 16/647454 [patent_app_country] => US [patent_app_date] => 2018-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52638 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16647454 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16343900 [patent_doc_number] => 20200308550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => TUMOR ORGANOID MODEL [patent_app_type] => utility [patent_app_number] => 16/646548 [patent_app_country] => US [patent_app_date] => 2018-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21004 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16646548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13982377 [patent_doc_number] => 20190060346 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => METHODS AND COMPOSITIONS FOR THE TREATMENT OF ISCHEMIC INJURY TO TISSUE USING THERAPEUTIC HYPOTHERMIA [patent_app_type] => utility [patent_app_number] => 16/119041 [patent_app_country] => US [patent_app_date] => 2018-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19246 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16119041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16267248 [patent_doc_number] => 20200268735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => Combination Therapy of Lasmiditan and a CGRP Antagonist for Use in the Treatment of Migraine [patent_app_type] => utility [patent_app_number] => 16/643668 [patent_app_country] => US [patent_app_date] => 2018-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12989 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16643668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14406809 [patent_doc_number] => 20190169248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => METHODS FOR PROTECTING DOPAMINERGIC NEURONS FROM STRESS AND PROMOTING PROLIFERATION AND DIFFERENTIATION OF OLIGODENDROCYTE PROGENITORS BY NRG-2 [patent_app_type] => utility [patent_app_number] => 16/116271 [patent_app_country] => US [patent_app_date] => 2018-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15999 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16116271 [rel_patent_id] =>[rel_patent_doc_number] =>)